The role of immunotherapy in the management of MEC and ACC is not clear, and PD-L1 expression levels have only been assessed using immunohistochemistry (IHC) in a few ACC cases and have not yet been investigated in MEC and TBP [9]. This evidence concerns the gene CD274 and adrenal cortex carcinoma.